Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Phoenix Clinical LLC

Neither a doctor nor a teaching hospital

Research payments

$8,343,890

255 payments

Through program year 2025, Phoenix Clinical LLC is reported as receiving $8,343,890 in research payments, across 255 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $44,777 18
2024 Research $577,764 22
2023 Research $3,527,605 68
2022 Research $3,144,828 53
2021 Research $527,125 26
2020 Research $231,788 31
2019 Research $290,003 37

Breakdown

Who paid Research payments · program years 2019–2025
  1. Bavarian Nordic A/S $4,971,747 73 payments
  2. Pfizer Inc. $2,011,499 62 payments
  3. Moderna TX, Inc. $521,176 44 payments
  4. Allergan Inc. $489,278 59 payments
  5. Eli Lilly and Company $299,453 4 payments
  6. Eisai Inc. $17,110 6 payments
  7. Novartis Pharmaceuticals Corporation $12,302 3 payments
  8. Sanofi US Services Inc. $10,443 1 payment
  9. GlaxoSmithKline, LLC. $6,000 2 payments
  10. Amgen Inc. $4,883 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $2,634,782 46 payments
  2. Nct05238025 $2,336,964 27 payments
  3. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $1,934,241 42 payments
  4. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $488,267 29 payments
  5. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $324,359 20 payments
  6. A Study of Orforglipron (Ly3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With Or Without Metformin And/?Or Sglt-2 Inhibitor (Achieve-5) $293,589 2 payments
  7. 46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) $77,711 11 payments
  8. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $77,258 20 payments
  9. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $35,101 7 payments
  10. 46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure $19,361 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record